Patents Examined by D Margaret M Seaman
  • Method for producing optically active pyrrolidine compounds
    Patent number: 11104662
    Abstract: The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water. (wherein R2 and R3 each independently represents a protecting group for carboxyl group).
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 31, 2021
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takao Teshima, Takafumi Yamagami, Tetsuo Yamaguchi, Junki Ando
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 11084831
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: August 10, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Use of substituted dihydroisoquinolinium salts for treating keratin materials, compositions and implementation processes
    Patent number: 11083679
    Abstract: The present invention relates to the use of one or more particular dihydroisoquinolinium salts of formula (I) for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium salts and one or more chemical oxidizing agents. The present invention also relates to one or more particular dihydroisoquinolinium salts and also to compositions containing them, in particular compositions comprising a physiologically acceptable medium.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 10, 2021
    Assignee: L'OREAL
    Inventors: Stéphane Sabelle, Aziz Fadli, Alexandra Charrier
  • Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
    Patent number: 11083718
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 10, 2021
    Assignee: IntraBio Ltd.
    Inventor: Michael Strupp
  • Bicyclic amide compounds and methods of use thereof
    Patent number: 11071721
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 27, 2021
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • Small molecule inhibitors of the JAK family of kinases
    Patent number: 11066406
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: July 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Philippe Fernandes, Paul J. Krawczuk, Mark S. Tichenor
  • 1-cyano-pyrrolidine compounds as USP30 inhibitors
    Patent number: 11066365
    Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable sat thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 20, 2021
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Kemp, Martin Stockley, Karl Gibson, Gavin Whitlock
  • Drug combinations to treat multiple myeloma
    Patent number: 11065240
    Abstract: This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: July 20, 2021
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Peter Lamb
  • Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound
    Patent number: 11053228
    Abstract: A condensed cyclic compound represented by Formula 1: Ar1-L1-Ar2??Formula 1 wherein, in Formula 1, Ar1, Ar2, and L are the same as described in the specification.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: July 6, 2021
    Assignees: SAMSUNG ELECTRONICS CO., LTD., SAMSUNG SDI CO., LTD.
    Inventors: Yongsik Jung, Soonok Jeon, Eunsuk Kwon, Sangmo Kim, Juhyun Kim, Jhunmo Son, Yeonsook Chung, Joonghyuk Kim
  • Compositions of CXCR4 inhibitors and methods of preparation and use
    Patent number: 11045461
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 29, 2021
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventor: Karel Marie Joseph Brands
  • Tungsten(VI) complexes for OLED application
    Patent number: 11043640
    Abstract: Described are to tungsten(VI) emitters. These materials can be used to fabricate OLEDs.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: June 22, 2021
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventor: Chi Ming Che
  • Pyridine derivative as ASK1 inhibitor and preparation method and use thereof
    Patent number: 11040968
    Abstract: Disclosed in the present invention are a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and also disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 22, 2021
    Inventors: Chengde Wu, Tao Yu, Ning Li, Shuhui Chen
  • Compounds containing Si atoms for optically active devices
    Patent number: 11040990
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 22, 2021
    Assignee: Merck Patent GmbH
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub
  • Dual mechanism inhibitors for the treatment of disease
    Patent number: 11028081
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 8, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Process for the synthesis of 6-chloromethyluracil
    Patent number: 11028057
    Abstract: The invention relates to a process for the synthesis of 6-chloromethyluracil (6-(chloromethyl)pyrimidin-2,4(1H,3H)-dione) from ethyl 4-chloroacetoacetate and S-methylisothiourea hemisulfate via isolation of the novel intermediate 6-(chloromethyl)-6-hydroxy-2-(methylthio)-5,6-dihydropyrimidin-4(1H)-one, and its subsequent treatment with aqueous sulfuric acid. Formula (I).
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 8, 2021
    Assignee: Procos S.P.A.
    Inventors: Fabio Morana, Stefano Gobbato, Jacopo Roletto, Paolo Paissoni
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11026930
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: June 8, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Brominated furanone derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient
    Patent number: 11021455
    Abstract: The present invention relates to a novel brominated furanone derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient, wherein the novel brominated furanone derivative or a pharmaceutically acceptable 5 salt thereof according to the present invention exhibits a quorum sensing inhibitory activity of bacteria and also can effectively inhibit the formation of biofilm of bacteria, and thus can be used as a pharmaceutical composition containing the same as an active ingredient, thereby having an effect of being useful, 10 for example, for periodontal diseases such as gingivitis and periodontitis, oral diseases, and the like.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: June 1, 2021
    Assignee: Seoul National University R&DB Foundation
    Inventors: Byeong Moon Kim, Bong Kyu Choi, Jae Hyun Sim, Eun Ju Ryu, Ji Su Park, Il Hak Bae
  • 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
    Patent number: 11014917
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Method for the synthesis and isolation of facial-tris-homoleptic phenylpyridinato iridium (III) photocatalysts
    Patent number: 11014078
    Abstract: Methods of synthesizing and isolating facial-tris-homoleptic phenylpyridinato iridium (III) photocatalysts are disclosed. Also disclosed are methods of recovering excess 2-phenylpyridine ligands from said syntheses.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: May 25, 2021
    Assignee: The Board of Regents for Oklahoma State University
    Inventors: Jimmie Dean Weaver, Kip Allen Teegardin
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 11000515
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 11, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson